TRISHULA THERAPEUTICS
Trishula is a privately held company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody, in collaboration with AbbVie. TTX-030 inhibits the activity of CD39, an enzyme that converts ATP to AMP, the initial step in the generation of adenosine in the tumor microenvironment. TTX-030 prevents the formation of immune-suppressive extracellular adenosine and maintains high levels of immune-activating extracellular ATP, stimulating dendritic and myeloid-derived cells necessary for both innate and adaptive immunity. Currently, TTX-030 is being studied in phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with advanced cancer (NCT03884556 and NCT04306900).
TRISHULA THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2020-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.trishulatx.com
Total Employee:
1+
Status:
Active
Contact:
650-509-5732
Email Addresses:
[email protected]
Technology used in webpage:
Google Maps U.S. Server Location
Similar Organizations
Eliksa Therapeutics
Eliksa Therapeutics is a biotechnology company that develops regenerative medicine.
Innovative BioTherapies
Innovative BioTherapies is a biotechnology company that develops medical devices to solve unmet medical needs.
iTolerance
iTolerance is a biotechnology company focused on regenerative medicine without immunosuppression.
Lytica Therapeutics
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.
Nira Skin
Nira Skincare transforms the anti aging skincare market by introducing Laser for reducing fine lines & wrinkles.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Seed Therapeutics
Seed Therapeutics is a biotech company that focuses on harnessing and engineering molecules.
Current Advisors List
Current Employees Featured
Founder
Investors List
Astellas Venture Management
Astellas Venture Management investment in Venture Round - Trishula Therapeutics
MPM Capital
MPM Capital investment in Venture Round - Trishula Therapeutics
Official Site Inspections
http://www.trishulatx.com Semrush global rank: 7.1 M Semrush visits lastest month: 890
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Trishula Therapeutics"
TTX-030 | anti-CD39 antibody | Trishula Therapeutics
Apr 12, 2022 Recent News. November 9, 2023 Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer PatientsSee details»
Trishula Therapeutics - Crunchbase Company Profile & Funding
Organization. Trishula Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; …See details»
Trishula Therapeutics, Inc. | LinkedIn
Trishula Therapeutics, Inc. Biotechnology Research South San Francisco, California 883 followers A clinical-stage cancer immunotherapy company developing TTX-030, a first-in-class anti-CD39 antibody.See details»
Press Release - trishulatx.com
Jan 21, 2021 Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer – Trishula Continues to Advance Development of TTX-030 in collaboration with AbbVieSee details»
Trishula Therapeutics - Overview, News & Similar companies
Apr 12, 2022 www.trishulatx.com. Revenue <$5 Million. Industry Business Services General Business Services . Recent News & Media. Trishula Therapeutics Initiates Phase 2 Trial of …See details»
Trishula Therapeutics Appoints Anil Singhal as Chief …
Jan 21, 2021 For more information, please visit www.trishulatx.com. Contacts: Janet [email protected] A photo accompanying this announcement is available at: https://www ...See details»
Trishula Therapeutics Appoints Anil Singhal as Chief ... - BioSpace
Jan 21, 2021 Currently, TTX-030 is being studied in phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with …See details»
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti …
Nov 9, 2023 For more information, please visit www.trishulatx.com. Media Contact: Julie Rathbun Rathbun Communications [email protected] 206-769-9219. SOURCE Trishula …See details»
Contact information for Trishula Therapeutics in South San …
Trishula Therapeutics 2268 Westborough Blvd Suite 302 #263 South San Francisco, CA 94080 1-650-509-5732 [email protected]See details»
Trishula Therapeutics - VentureRadar
"Trishula is dedicated to improving the outcomes for people with cancer. TTX-030 is a first-in-class antibody that inhibits the activity of CD39.See details»
- Canaan
Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.See details»
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti …
Nov 9, 2023 Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today announced the initiation of a randomized Phase 2 trial to evaluate the efficacy and …See details»
Trishula - Abingworth LLP
Trishula Therapeutics, a spinout from Tizona, is a clinical-stage antibody company focused on immunotherapy. Its first-in-class anti-CD39 program (TTX-030) is partnered with AbbVie and …See details»
Trishula Therapeutics Appoints Anil Singhal as Chief
Jan 21, 2021 For more information, please visit www.trishulatx.com. Contacts: Janet Graesser [email protected] 917-685-8799. A photo accompanying this announcement is …See details»
Trishula Therapeutics Presents Positive Results from
Sep 16, 2024 Trishula is a privately held biotechnology company dedicated to the development of TTX-030. For more information, please visit www.trishulatx.com. Media Contact. Julie …See details»
Trishula Therapeutics Announces Promising Early Phase 1b Data of …
Apr 12, 2022 /PRNewswire/ -- Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class investigational anti-CD39 antibody...See details»
Trishula Therapeutics Presents Positive Results from Phase 1 Trial …
Sep 16, 2024 For more information, please visit www.trishulatx.com. Media Contact: Julie Rathbun Rathbun Communications [email protected] 206-769-9219. SOURCE Trishula …See details»
Press Release - trishulatx.com
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients – Trishula will continue its collaboration with AbbVie …See details»
Press Releases and the latest News for Trishula Therapeutics
September 16, 2024 Trishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer Patients. November 9, 2023 Trishula …See details»